•   
  •   
  •   

US Q&A: How far can Trump go in pushing a COVID-19 vaccine that isn't ready?

00:11  10 october  2020
00:11  10 october  2020 Source:   latimes.com

Children will not likely see a coronavirus vaccine until late 2021: Experts

  Children will not likely see a coronavirus vaccine until late 2021: Experts America's youngest may not be vaccinated until late next year, health experts told ABC News. © Brian Snyder/Reuters, FILE Boston Medical Center pediatrician Dr. Sara Stulac talks to the parents of two-year old Areeba Syed on the steps of their home after Areeba received a routine check-up in Boston, May 8, 2020. Despite recent evidence that children may play a larger role in the community spread of COVID-19, experts say the delay is appropriate, because a vaccine should be tested in adults first to ensure it's safe and effective before being tested in children.

As President Trump pushes the possibility of a vaccine this year, the C.D.C. has outlined technical scenarios to state public health officials for The agency also said its plans were as yet hypothetical, noting, “The Covid - 19 vaccine landscape is evolving and uncertain, and these scenarios may evolve

Trump doesn' t have Covid 19 and there is War coming!! From all angles!! (Must Video). Friday, October 2, 2020 17:19. % of readers think this story is Fact. Add your two cents. Nothing is at face value!! We must let go of the Politics and other belief systems they have set in place and realize that

We all want a COVID-19 vaccine as soon as we can get it, and we'd like to know that the vaccine is safe and actually works. Those two desires are at cross-purposes now, since the testing required to vet a new vaccine takes time.

a close up of a device: Vials of a single-dose COVID-19 vaccine being developed by Johnson & Johnson. (Cheryl Gerber / Courtesy of Johnson & Johnson) © (Cheryl Gerber / Courtesy of Johnson & Johnson) Vials of a single-dose COVID-19 vaccine being developed by Johnson & Johnson. (Cheryl Gerber / Courtesy of Johnson & Johnson)

President Trump has made clear that his top priority is speed. For a time, his administration rejected the Food & Drug Administration's proposed criteria for assessing vaccine candidates — criteria which make it all but impossible to have a vaccine available by election day.

NFL reportedly discussing playoff bubble following coronavirus cases

  NFL reportedly discussing playoff bubble following coronavirus cases The NFL has already postponed one game and had players test positive for the coronavirus on multiple teams, which has led to talk of potentially needing a bubble plan going forward. That is still on the table, at least for the postseason. © Jasen Vinlove-USA TODAY Sports Discussions about playing games in a postseason bubble have picked up for the NFL internally, according to Jason La Canfora of CBS Sports. The most viable plan would involve the two conference championship games being played in a bubble.

Donald Trump 's decision to kill Covid - 19 relief negotiations may be a brave stand on principle, ultimately siding with conservatives who are against more massive deficit-financed spending, but it is also a very risky political The White House said it would back a Covid - 19 relief bill of .6 trillion.

Trump , 74, revealed this week that he and his wife, Melania, tested positive for Covid - 19 . He was flown to Walter Reed on Friday evening after experiencing symptoms at the request of Dr. Conley. Multiple other politicians and White House officials have also revealed positive tests for the virus since then.

This week, the White House relented and approved the FDA's proposal. But the question remains: Could Trump force regulators or companies to give the public a COVID-19 vaccine that didn't meet scientific standards?

The short answer: It depends.

To play out the possibilities, you'll need to understand some facts about vaccine science, the political calculations and commercial motives of the central characters, and what it will take to get Americans to trust a vaccine so we have a shot at returning to something resembling normal life.

Let's get started.

Why do we think Trump values speed more than safety?

There's no question the president would like to see a vaccine approved before ballots are cast. He appears eager to show voters that he responded to the pandemic by getting a vaccine developed and deployed in record time.

A COVID-19 vaccine by Election Day? Here are the 3 things that would need to happen, and soon.

  A COVID-19 vaccine by Election Day? Here are the 3 things that would need to happen, and soon. Could an approved coronavirus vaccine be released before Election Day on Nov. 3? It's extremely unlikely but not impossible, experts say.President Donald Trump on Monday said, "vaccines are coming momentarily," and he has promised on multiple occasions that one will be ready before the election, now less than a month away.

President Donald Trump ’s medical condition has continued to improve as he recovers from an illness brought on by a Covid - 19 infection, and he may be well enough to be released from U.S. President Donald Trump works in a conference room while receiving treatment after testing positive for Covid - 19 .

Play video Trump on Covid - 19 in his own words from BBCTrump on Covid - 19 in his own words. President Trump has been criticised for saying Americans should not fear Covid - 19 Image caption The rule would have effectively made it impossible for a vaccine to hit the market before the 3

“Moving faster than anticipated. Good news ahead!” he tweeted in June. “Now the Vaccines (Plus) are coming, and fast!” he tweeted in early September. “The Democrats are just ANGRY that the vaccine and delivery are so far ahead of schedule. They hate what they are seeing,” he complained later that month.

His preoccupation with that timing has caused him to clash with officials who said vaccine approvals might not come until 2021. Chief among them has been Coronavirus Task Force member Dr. Anthony Fauci, the nation's top infectious diseases specialist. But lately, it’s been FDA Commissioner Stephen M. Hahn’s time in the barrel.

“New FDA Rules make it more difficult for them to speed up vaccines for approval before Election Day. Just another political hit job!” he tweeted at Hahn.

Although Trump will almost certainly miss his self-imposed election-day deadline, his administration is still on track to achieve a speed record. Vaccines typically take about a decade to develop, test and deploy. Even if it takes several more months for the first COVID-19 vaccine to clear the FDA's hurdles, it will have emerged in roughly a year from the time the virus was identified.

Has the FDA done something that could delay a vaccine?

Not with that intent.

The FDA's guidelines to vaccine makers require them to keep track of each person in their clinical trial for two months after receiving a dose of vaccine. That's how long it should take for roughly half of the vaccine-related "adverse events" to crop up, according to Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research. That lengthy follow-up is needed to boost the agency’s confidence in the vaccine safety data it reviews.

With that requirement in place, there is no way for any vaccine clinical trial in the U.S. to wrap up in time for a pre-election day announcement. Perhaps that's why Trump shifted his focus this week and began touting the experimental antibody treatment from Regeneron that he received at Walter Reed National Military Medical Center.

Polio campaign of the 1950s provides a sound model for what the U.S. needs for COVID-19

  Polio campaign of the 1950s provides a sound model for what the U.S. needs for COVID-19 COVID-19 vaccines are in development but there is widespread distrust. Looking to the polio epidemic and vaccine could teach us how to deal with it.The United States is very likely speeding toward the approval and distribution of a vaccine that a sizable portion of the population will forgo. A new Pew Research Center survey reveals a 21 percentage point drop since May — from 72% to 51% — among adults who would get a COVID-19 vaccine today, with a decline “across all major political and demographic groups.

Trump delivered the news shortly after he confirmed that his aide Hope Hicks had tested positive. According to media reports, she traveled with the president multiple times recently, including to the debate with Joe Biden in Cleveland, Ohio on Tuesday. Hicks was also on the presidential aircraft to fly

So far , she said, the state’s supply of remdesivir remains adequate. Dr. White and his colleagues were considering a weighted lottery before the remdesivir These outcome data are buried in the patients’ electronic health records. Were the patients participating in a weighted lottery, it would be far easier to

Workers at Regeneron Pharmaceuticals inspect vials of the company's experimental antibody treatment for COVID-19. (Regeneron) © (Regeneron) Workers at Regeneron Pharmaceuticals inspect vials of the company's experimental antibody treatment for COVID-19. (Regeneron)

What about the companies that made the vaccines? Don't they want approval as quickly as possible?

The companies that field a vaccine that safely protects against coronavirus infection — even if it only prevents infection in just 50% of cases — will become rich and respected. (There probably will be more than one vaccine candidate authorized by the FDA.)

But the company whose vaccine sickens a significant number of Americans will wish it had never heard of Operation Warp Speed, the government program to accelerate vaccine development.

That company probably wouldn't face financial consequences for sickening its customers: Since the 1980s, the feds have shielded the makers of virtually all vaccines from liability to keep them from exiting a business that comes with modest profits and lots of lawsuits alleging injury. But a COVID-19 vaccine that causes serious side effects in a broad swath of people would be a serious PR disaster.

Speeding up the testing process by a couple of months would not pay off for them in the long run.

Last month, nine companies leading the race to produce COVID-19 vaccines pledged not to seek FDA authorization or approval until the safety and efficacy of their products has been established in legitimate clinical trials. Their joint declaration was intended to demonstrate their “commitment to uphold the integrity of the scientific process,” they said.

China Covid-19 vaccine: Inside the company at the forefront of China's push to develop a coronavirus vaccine

  China Covid-19 vaccine: Inside the company at the forefront of China's push to develop a coronavirus vaccine Inside the white, sterile walls of a new building on the southern outskirts of Beijing, two employees donning masks and rubber gloves are busy pipetting a clear, colorless liquid into rows of small vials. © NICOLAS ASFOURI/AFP/AFP via Getty Images In this picture taken on April 29, 2020, an engineer shows an experimental vaccine for the COVID-19 coronavirus that was tested at the Quality Control Laboratory at the Sinovac Biotech facilities in Beijing.

The statement was widely seen as a rebuke to President Trump.

Can Trump change the FDA's criteria for evaluating vaccine candidates? Can he force the FDA to approve one?

Yes. Trump has the legal authority to make the FDA approve an experimental vaccine on his say-so because he is the chief executive and this is an executive agency.

In the midst of a national emergency, the FDA has a great deal of legal latitude in granting emergency use authorization to drugs or vaccines. It can also modify its criteria as circumstances change.

The Trump administration has overruled scientists on a wide range of issues overseen by several federal regulatory agencies. Under its regulation-reduction initiatives, it has loosened air pollution and clean water strictures, eased automobile emission standards, and relaxed safety protections for workers. Most of these rollbacks have been made by discounting scientific studies used to undergird existing regulations or by changing the way a regulation's impact is measured.

The president has chafed against the FDA’s time-consuming drug-approval record for years. With far less fanfare, he has sought to speed drug approvals, change the way clinical trials are conducted, and make the FDA give dying patients early access to drugs it has not deemed safe or effective.

Such efficiencies have allowed a cautious, science-driven agency to respond more quickly to the urgent needs of a pandemic. But if a Trump official were determined to bend the FDA's schedule for political reasons, the administration's track record of shifting scientific goalposts would make it easier to do so.

Protecting the profits of a few could prevent vaccine access for all

  Protecting the profits of a few could prevent vaccine access for all India and South Africa have put forward a novel proposal to replace our current competition-driven approach with cooperation. At a meeting on Oct. 15, they will be asking the World Trade Organization (WTO) to temporarily relax its rules to allow for more international collaboration in the manufacture of the vaccines and medicines - even without authorization from the companies that created them. Theirs is an ambitious gambit, but one that deserves support. require(["medianetNativeAdOnArticle"], function (medianetNativeAdOnArticle) { medianetNativeAdOnArticle.

Are there non-scientific reasons for the FDA to impose time-consuming requirements on vaccine trials?

Yes. But they’re not the reasons Trump has alleged, or that his conspiratorial insinuations might have you believe.

The FDA urgently needs to shore up Americans’ confidence in the safety of the coronavirus vaccine — it's the only way to ensure that a high proportion of Americans are willing to take a vaccine it approves.

That's a tall order. As recently as May, 72% of Americans said they “probably” or “definitely” would get vaccinated once COVID-19 immunizations were available, and just 27% said they probably or definitely would not, according to a Pew Research survey. By September, 49% of Americans told Pew said they "probably" or "definitely" would not get the vaccine, and only 51% said they "probably" or "definitely" would.

The goal of a vaccine is to establish “herd immunity.” That's when so many people have been made immune to the coronavirus that it can't easily find new people to infect. Even those who can't (or won't) take the vaccine will be protected because the virus won't have an easy path to reach them. At that point, new transmissions will slow and outbreaks will be fewer and more short-lived. And the pandemic will be over.

Experts have estimated that to achieve such population-wide protection in the United States, 70% to 80% of the U.S. population will need to gain immunity as a result of a COVID-19 vaccine or because they've survived the disease themselves.

Those herd immunity estimates are really rough, and they will vary from place to place and among populations. For instance, vaccination rates might need to be higher among front-line workers and people of color.

But people of color, already disproportionately affected by the pandemic, have endured a long history of abuses at the hands of medical researchers. Their resulting mistrust of the medical establishment will heighten the challenge of persuading them to take the COVID-19 vaccine.

a man wearing a neck tie: A woman receives an injection as part of a clinical trial for a COVID-19 vaccine. (Johnson & Johnson) © (Johnson & Johnson) A woman receives an injection as part of a clinical trial for a COVID-19 vaccine. (Johnson & Johnson)

And the vaccination rates needed to achieve herd immunity might well exceed 70% or 80%, since the first crop of vaccines won't be 100% effective. In June, the FDA said it would consider approving vaccine candidates that prevent disease or decrease its severity in as little as 50% of those who get it.

With the proportion of Americans willing to get vaccinated well below the threshold needed for herd immunity, the FDA has some reassuring to do.

There’s science in that, but lots of optics too.

This story originally appeared in Los Angeles Times.

Legacy Museum reopens, Hawaii gets visitors, Boston Symphony Orchestra .
How the COVID-19 pandemic is affecting every stateStart the day smarter. Get all the news you need in your inbox each morning.

usr: 1
This is interesting!